Pfizer’s blockbuster drug tafamidis for the treatment of the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM) needs at least a 96% discount off its list price to be considered ...

Novel directed therapies for transthyretin cardiac amyloidosis (ATTR) have been shown to improve outcomes and reduce the long-term negative effects of unchecked amyloid proliferation in patients with ...

It is possible for transthyretin amyloid cardiomyopathy (ATTR-CM, also called cardiac ATTR amyloidosis) to be reversed with antibody treatment, as suggested by rare cases of patients who had their ...

The diagnosis of cardiac ATTR amyloidosis is frequently missed or delayed due to the transitional requirement that a tissue sample (biopsy) is required to confirm the diagnosis. A nuclear medicine ...

Chicago, Illinois (Embargoed until 1:33 p.m. CDT, Sunday, June 25, 2023)—Researchers have identified the optimal tracer kinetic model to quantify 18F-flutemetamol myocardial uptake in patients with ...

Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive cardiomyopathy. Patisiran, an RNA ...

Transthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal disease caused by misfolded transthyretin. Despite advances in slowing disease progression, there is no available treatment that ...

A new study used data from the UK Biobank to analyze the genes of 469,789 people in the UK and found that one in 1,000 possessed genetic variants with a likely link to cardiac transthyretin (ATTR) ...

The same abnormal proteins that can build up in your heart when you have transthyretin cardiac amyloidosis (ATTR-CM) can also leave deposits in your spine, resulting in spinal stenosis. Spinal ...

Amyloid heart disease occurs when amyloid fibrils build up in the heart, making it more difficult for the heart to pump blood around the body. Eventually, this can lead to heart failure. People can ...